Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
Abstract Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory analysis of the RECOURSE randomized clinical trial (RCT) established two categories, a good prognosis corresponding to subjects having a low tumor...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/79955248229f4b8ab9ff4d86bc53b994 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:79955248229f4b8ab9ff4d86bc53b994 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:79955248229f4b8ab9ff4d86bc53b9942021-12-02T16:08:07ZPrediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data10.1038/s41598-021-93732-52045-2322https://doaj.org/article/79955248229f4b8ab9ff4d86bc53b9942021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93732-5https://doaj.org/toc/2045-2322Abstract Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory analysis of the RECOURSE randomized clinical trial (RCT) established two categories, a good prognosis corresponding to subjects having a low tumor burden and indolent disease. Other models in refractory mCRC are the FAS-CORRECT and Colon Life nomogram. The main objective was to externally validate the prognostic factors of the RECOURSE and FAS-CORRECT trials, and the Colon Life nomogram in a multicenter, real-world series of mCRC treated in 3rd and successive lines with trifluridine/tipiracil. The secondary aim was to develop an OS predictive model, TAS-RECOSMO. Between 2016 and 2019, 244 patients were recruited. Median OS was 8.15 vs 8.12 months for the poor (85% of the subjects) and good (15%) prognosis groups from the RESOURCE trial, respectively, log-rank p = 0.9. The most common grade 3–4 toxicities were neutropenia (17%), asthenia (6%), and anemia (5%). The AFT lognormal model TAS-RECOSMO included six variables: ECOG-PS, KRAS/NRAS/BRAF mutation status, time between diagnosis of metastasis and beginning of trifluridine/tipiracil, NLR, CEA, and alkaline phosphatase. The model’s bootstrapped bias-corrected c-index was 0.682 (95% CI, 0.636–0.722). The factors from the Colon Life model, FAS-CORRECT, and RECOURSE displayed a c-index of 0.690, 0.630, and 0.507, respectively. TAS-RECOSMO, FAS-CORRECT, and the Colon Life nomogram appear to predict OS in patients with refractory mCCR who begin trifluridine/tipiracil treatment in the real world. The prognostic groups of the RECOURCE RCT were unable to capture the situation of real-world subjects treated with trifluridine/tipiracil in this series.Ana Fernández MontesAlberto Carmona-BayonasPaula Jimenez-FonsecaFrancisca Vázquez RiveraNieves Martinez LagoMarta Covela RúaAntía Cousillas CastiñeirasPaula Gonzalez VillarroelJuan De la Cámara GómezJosé Carlos Méndez MéndezCarmen Carriles FernándezManuel Sanchez CánovasTeresa Garcia GarcíaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Ana Fernández Montes Alberto Carmona-Bayonas Paula Jimenez-Fonseca Francisca Vázquez Rivera Nieves Martinez Lago Marta Covela Rúa Antía Cousillas Castiñeiras Paula Gonzalez Villarroel Juan De la Cámara Gómez José Carlos Méndez Méndez Carmen Carriles Fernández Manuel Sanchez Cánovas Teresa Garcia García Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data |
| description |
Abstract Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory analysis of the RECOURSE randomized clinical trial (RCT) established two categories, a good prognosis corresponding to subjects having a low tumor burden and indolent disease. Other models in refractory mCRC are the FAS-CORRECT and Colon Life nomogram. The main objective was to externally validate the prognostic factors of the RECOURSE and FAS-CORRECT trials, and the Colon Life nomogram in a multicenter, real-world series of mCRC treated in 3rd and successive lines with trifluridine/tipiracil. The secondary aim was to develop an OS predictive model, TAS-RECOSMO. Between 2016 and 2019, 244 patients were recruited. Median OS was 8.15 vs 8.12 months for the poor (85% of the subjects) and good (15%) prognosis groups from the RESOURCE trial, respectively, log-rank p = 0.9. The most common grade 3–4 toxicities were neutropenia (17%), asthenia (6%), and anemia (5%). The AFT lognormal model TAS-RECOSMO included six variables: ECOG-PS, KRAS/NRAS/BRAF mutation status, time between diagnosis of metastasis and beginning of trifluridine/tipiracil, NLR, CEA, and alkaline phosphatase. The model’s bootstrapped bias-corrected c-index was 0.682 (95% CI, 0.636–0.722). The factors from the Colon Life model, FAS-CORRECT, and RECOURSE displayed a c-index of 0.690, 0.630, and 0.507, respectively. TAS-RECOSMO, FAS-CORRECT, and the Colon Life nomogram appear to predict OS in patients with refractory mCCR who begin trifluridine/tipiracil treatment in the real world. The prognostic groups of the RECOURCE RCT were unable to capture the situation of real-world subjects treated with trifluridine/tipiracil in this series. |
| format |
article |
| author |
Ana Fernández Montes Alberto Carmona-Bayonas Paula Jimenez-Fonseca Francisca Vázquez Rivera Nieves Martinez Lago Marta Covela Rúa Antía Cousillas Castiñeiras Paula Gonzalez Villarroel Juan De la Cámara Gómez José Carlos Méndez Méndez Carmen Carriles Fernández Manuel Sanchez Cánovas Teresa Garcia García |
| author_facet |
Ana Fernández Montes Alberto Carmona-Bayonas Paula Jimenez-Fonseca Francisca Vázquez Rivera Nieves Martinez Lago Marta Covela Rúa Antía Cousillas Castiñeiras Paula Gonzalez Villarroel Juan De la Cámara Gómez José Carlos Méndez Méndez Carmen Carriles Fernández Manuel Sanchez Cánovas Teresa Garcia García |
| author_sort |
Ana Fernández Montes |
| title |
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data |
| title_short |
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data |
| title_full |
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data |
| title_fullStr |
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data |
| title_full_unstemmed |
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data |
| title_sort |
prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/79955248229f4b8ab9ff4d86bc53b994 |
| work_keys_str_mv |
AT anafernandezmontes predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT albertocarmonabayonas predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT paulajimenezfonseca predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT franciscavazquezrivera predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT nievesmartinezlago predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT martacovelarua predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT antiacousillascastineiras predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT paulagonzalezvillarroel predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT juandelacamaragomez predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT josecarlosmendezmendez predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT carmencarrilesfernandez predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT manuelsanchezcanovas predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata AT teresagarciagarcia predictionofsurvivalinpatientswithadvancedrefractorycolorectalcancerintreatmentwithtrifluridinetipiracilrealworldvsclinicaltrialdata |
| _version_ |
1718384605188325376 |